Clinical Trials Directory

Trials / Unknown

UnknownNCT04548401

Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Nanjing Medical University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers

Summary

Deficits in memory, executive function, and language are common cognitive sequelae of aneurysmal subarachnoid hemorrhage (aSAH). Previous study demonstrated that post-treatment antiplatelet therapy reduced risk for delayed cerebral ischemia caused by aSAH. However, the effect of antiplatelet therapy on cognition after aSAH is unclear. The aim of this study was to assess the effect of antiplatelet therapy on cognition after aSAH.

Conditions

Interventions

TypeNameDescription
DRUGAntiplatelet Drugaspirin and/or clopidogrel or ticagrelor

Timeline

Start date
2019-11-01
Primary completion
2021-10-31
Completion
2021-12-31
First posted
2020-09-14
Last updated
2020-09-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04548401. Inclusion in this directory is not an endorsement.